Risperidone failed to improve polydipsia-hyponatremia of the schizophrenic patients

• Published in: Psychiatry and clinical neurosciences Vol. 56; no. 1; pp. 107 - 110
• Main Authors: Kawai, Nobutoshi, Baba, Atsuomi, Suzuki, Toshihito
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Science Asia Pty. Ltd 01.02.2002; Blackwell Publishing
• Subjects: Adult; Antipsychotic Agents - therapeutic use; Biological and medical sciences; clozapine; Humans; hyponatremia; Hyponatremia - drug therapy; Male; Medical sciences; Neuropharmacology; Pharmacology. Drug treatments; polydipsia; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; risperidone; Risperidone - therapeutic use; schizophrenia; Schizophrenia - drug therapy; Schizophrenic Psychology; Treatment Failure; water intoxication; Water Intoxication - drug therapy; Water Intoxication - etiology; Hydroelectrolytic balance disorder; Neuroleptic; Psychotropic; Schizophrenia; Male; Serotonine receptor; Inorganic element; Dose activity relation; Psychosis; Antagonist; Risperidone; Polydipsia; Human; Hyponatremia; Dopamine receptor; Dopamine antagonist; Serotonin antagonist; Treatment efficiency; Symptomatology; Metabolic disorder; Concomitant disease; Chemotherapy; Treatment; Follow up study; Atypical
• ISSN: 1323-1316; 1440-1819
• DOI: 10.1046/j.1440-1819.2002.00937.x

The effect of risperidone on polydipsia‐hyponatremia was evaluated in six hospitalized schizophrenic patients. The normalized diurnal weight gain (NDWG), urine‐specific gravity (USG), urine and plasma osmolarity, and serum sodium were monitored during 9 months of risperidone treatment. The dose of risperidone (mean ± SD = 8.0 ± 1.0, range = 6–9 mg/day) was determined as approximately half of the haloperidol‐equivalent dose of previous neuroleptics. Before risperidone treatment, the mean (± SD) BPRS score was 23.5 ± 7.1; no significant improvement was observed after risperidone (22.0 ± 7.5). The subjects showed relatively high serum prolactin before risperidone treatment (mean ± SD = 16.5 ± 9.7 ng/mL), that was not significantly decreased by risperidone (14.2 ± 7.9 ng/mL). The monthly means (± SD) of NDWG and USG before risperidone were 5.5 ± 1.5 (%) and 1.002 ± 0.001, respectively. These and other indices did not significantly improve throughout the study period. Although the sample size is relatively small, our preliminary data showed that risperidone might not be effective on polydipsia‐hyponatremia of schizophrenic patients.